RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The GeparX study investigated whether denosumab as add-on treatment to nab-paclitaxel-based neoadjuvant chemotherapy (NACT) with two different schedules (125 mg/m² weekly vs. day 1, 8 every 22 days) may increase pathologic complete response (pCR) rate. The addition of denosumab to NACT did not improve pCR rates as recently published. In this study, we investigated whether receptor activator of nuclear factor-kappa B (RANK) expression, as part of the denosumab target pathway: (i) may retrospectively identify a subgroup of patients with additional clinical benefit of denosumab or (ii) may predict response to nab-paclitaxel NACT.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin Cancer Res

Title: Clinical cancer research : an official journal of the American Association for Cancer Research

Publisher: American Association for Cancer Research (AACR)

ISSN (Electronic): 1557-3265

ISSN (Print): 1078-0432

Publication date (Electronic): Nov 14 2023

Volume: 29

Issue: 22

Affiliations

[1 ] Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

[2 ] National Center for Tumour Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.

[3 ] German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany.

[4 ] Onkologische Schwerpunktpraxis Bielefeld, Bielefeld, Germany.

[5 ] Helios Klinikum Berlin-Buch, Berlin, Germany.

[6 ] Gemeinschaftspraxis Hämatologie/Intern. Onkologie, München, Germany.

[7 ] Universitätsklinikum Erlangen, Erlangen, Germany.

[8 ] Department of Gynecology and Gynecological Oncology, Agaplesion Markus Krankenhaus, Frankfurt, Germany.

[9 ] Evang. Kliniken Essen-Mitte, Essen, Germany.

[10 ] Nationales Centrum für Tumorerkrankungen, Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, Germany.

[11 ] German Breast Group, Neu-Isenburg, Germany.

[12 ] Kantonsspital St. Gallen, Brustzentrum, Departement Interdisziplinäre medizinische Dienste, St. Gallen, Switzerland.

[13 ] Sana Klinikum Offenbach, Offenbach, Germany.

[14 ] Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum Köln, Germany Universität Köln, Zentrum familiärer Brust- und Eierstockkrebs, Köln, Germany.

[15 ] Rotkreuzklinikum, München, Germany.

[16 ] Institute of Pathology, Philipps-University Marburg and University Hospital Marburg (UKGM), Marburg, Germany.

Article

Publisher Item ID: 729129

DOI: 10.1158/1078-0432.CCR-23-1801

PubMed ID: 37725572

SO-VID: 90f9b53b-f021-4346-98b9-196ef367a634

History

Data availability:

Comments

Comment on this article

scite_

Cited by 1

Correlation of RANK and RANKL with mammographic density in primary breast cancer patients
Authors: Marius Wunderle, Felix Heindl, Annika S. Behrens …

See all cited by